CELSENTRI 25 mg, film-coated tablet 120 tablets
Active ingredients: Maraviroc
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet120 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CELSENTRI 25 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) aluminium avec fermeture de sécurité enfant de 120 comprimé(s)
- Marketing authorisation holder
- VIIV HEALTHCARE UK (ROYAUME-UNI)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 1 Apr 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60992262CIP73010337CIP133400930103371Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MARAVIROCcomprimé | 25 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.